BCRX vs. ALKS, IONS, FOLD, LGND, DVAX, MNKD, CLDX, NVAX, OPK, and GERN
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.
BioCryst Pharmaceuticals vs.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, Alkermes had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 18 mentions for Alkermes and 7 mentions for BioCryst Pharmaceuticals. Alkermes' average media sentiment score of 1.20 beat BioCryst Pharmaceuticals' score of 0.97 indicating that Alkermes is being referred to more favorably in the news media.
BioCryst Pharmaceuticals presently has a consensus price target of $15.57, indicating a potential upside of 98.87%. Alkermes has a consensus price target of $39.38, indicating a potential upside of 17.46%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Alkermes.
Alkermes has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Alkermes has a net margin of 23.57% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Alkermes' return on equity of 30.80% beat BioCryst Pharmaceuticals' return on equity.
BioCryst Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Alkermes received 213 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 70.41% of users gave Alkermes an outperform vote while only 66.80% of users gave BioCryst Pharmaceuticals an outperform vote.
Summary
Alkermes beats BioCryst Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:BCRX) was last updated on 3/28/2025 by MarketBeat.com Staff
